We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Vertex Pharmaceuticals is off to a running start with its new hepatitis C drug. The Cambridge company said had it generated $74.5 million in sales of telaprevir in the quarter that ended June 30. Boston Globe
